TY - STD TI - Macmillan. Health inequalities: time to talk. 2019. https://macmillan.org.uk/assets/health-inequalities-paper-april-2019.pdf. Accessed 15 Mar 2020. UR - https://macmillan.org.uk/assets/health-inequalities-paper-april-2019.pdf ID - ref1 ER - TY - JOUR AU - Forrest, L. F. AU - Adams, J. AU - Wareham, H. AU - Rubin, G. AU - White, M. PY - 2013 DA - 2013// TI - Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis JO - PLoS Med VL - 10 ID - Forrest2013 ER - TY - JOUR AU - Aarts, M. J. AU - Lemmens, V. E. P. P. AU - Louwman, M. W. J. AU - Kunst, A. E. AU - Coebergh, J. W. W. PY - 2010 DA - 2010// TI - Socioeconomic status and changing inequalities in colorectal cancer? A review of the associations with risk, treatment and outcome JO - Eur J Cancer VL - 46 ID - Aarts2010 ER - TY - JOUR AU - Halpern, M. T. PY - 2015 DA - 2015// TI - Cancer disparities research: it is time to come of age JO - Cancer. VL - 121 ID - Halpern2015 ER - TY - JOUR AU - Dranitsaris, G. AU - Zhu, X. AU - Adunlin, G. AU - Vincent, M. D. PY - 2018 DA - 2018// TI - Cost effectiveness vs affordability in the age of immuno-oncology cancer drugs JO - Expert Rev Pharmacoecon Outcomes Res VL - 18 ID - Dranitsaris2018 ER - TY - STD TI - NCCN. Clinical practice guidelines in oncology: non-small cell lung cancer. 2020. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 23 Mar 2020. UR - http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf ID - ref6 ER - TY - STD TI - IQVIA Institute. Global oncology trends 2019 therapeutics, clinical development and health system implications institute report. 2019. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/global-oncology-trends-2019.pdf?_=1587463035271. Accessed 14 Mar 2020. UR - https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/global-oncology-trends-2019.pdf?_=1587463035271 ID - ref7 ER - TY - JOUR AU - McClellan, K. A. AU - Avard, D. AU - Simard, J. AU - Knoppers, B. M. PY - 2013 DA - 2013// TI - Personalized medicine and access to health care: potential for inequitable access? JO - Eur J Hum Genet VL - 21 ID - McClellan2013 ER - TY - JOUR AU - Ward, M. M. PY - 2012 DA - 2012// TI - Personalized therapeutics: a potential threat to health equity JO - J Gen Intern Med VL - 27 ID - Ward2012 ER - TY - JOUR AU - James, J. E. PY - 2014 DA - 2014// TI - Personalised medicine, disease prevention, and the inverse care law: more harm than benefit? JO - Eur J Epidemiol VL - 29 ID - James2014 ER - TY - JOUR AU - Huey, R. W. AU - Hawk, E. AU - Offodile, A. C. PY - 2019 DA - 2019// TI - Mind the gap: precision oncology and its potential to widen disparities JO - J Onco Practice VL - 15 ID - Huey2019 ER - TY - JOUR AU - Schwaederle, M. AU - Zhao, M. AU - Lee, J. J. AU - Eggermont, A. M. AU - Schilsky, R. L. AU - Mendelsohn, J. PY - 2015 DA - 2015// TI - Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials JO - J Clin Oncol VL - 33 ID - Schwaederle2015 ER - TY - JOUR AU - Mok, T. S. AU - Wu, Y. -. L. AU - Thongprasert, S. AU - Yang, C. -. H. AU - Chu, D. -. T. AU - Saijo, N. PY - 2009 DA - 2009// TI - Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma JO - N Engl J Med VL - 361 ID - Mok2009 ER - TY - JOUR AU - Moher, D. AU - Liberati, A. AU - Tetzlaff, J. AU - Altman, D. G. PY - 2009 DA - 2009// TI - Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement JO - PLoS Med VL - 6 ID - Moher2009 ER - TY - STD TI - Ross JS. Targeted therapies for cancer. In: Gingsburg GS, Willard HF, editors. Essentials of genomic and personalized medicine. 1st ed. Amsterdam; Boston; London: Elsevier; 2010. p. 532–547. ID - ref15 ER - TY - STD TI - Higgins J, Deek JJ. Chapter 7: selecting studies and collecting data. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 510 [updated March 2011]. Chichester: Wiley; 2011. ID - ref16 ER - TY - JOUR AU - Motheral, B. AU - Brooks, J. AU - Clark, M. A. AU - Crown, W. H. AU - Davey, P. AU - Hutchins, D. PY - 2003 DA - 2003// TI - A checklist for retrospective database studies—report of the ISPOR task force on retrospective databases JO - Value Health VL - 6 ID - Motheral2003 ER - TY - JOUR AU - Braveman, P. A. AU - Cubbin, C. AU - Egerter, S. AU - Chideya, S. AU - Marchi, K. S. AU - Metzler, M. PY - 2005 DA - 2005// TI - Socioeconomic status in health research one size does not fit all JO - JAMA. VL - 294 ID - Braveman2005 ER - TY - JOUR AU - Higgins, J. P. T. AU - Thompson, S. G. PY - 2002 DA - 2002// TI - Quantifying heterogeneity in a meta-analysis JO - Stat Med VL - 21 ID - Higgins2002 ER - TY - JOUR AU - Egger, M. AU - Smith, G. D. AU - Schneider, M. AU - Minder, C. PY - 1997 DA - 1997// TI - Bias in meta-analysis detected by a simple, graphical test JO - BMJ. VL - 315 ID - Egger1997 ER - TY - JOUR AU - Pensa, M. AU - Swede, H. AU - Brockmeyer, J. A. AU - Gregorio, D. I. PY - 2009 DA - 2009// TI - Patterns of HER2 testing in the management of primary breast cancer JO - Cancer Epidemiol VL - 33 ID - Pensa2009 ER - TY - JOUR AU - Lund, M. J. AU - Butler, E. N. AU - Hair, B. Y. AU - Ward, K. C. AU - Andrews, J. H. AU - Oprea-Ilies, G. PY - 2010 DA - 2010// TI - Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes JO - Cancer. VL - 116 ID - Lund2010 ER - TY - JOUR AU - Ferrusi, I. L. AU - Earle, C. C. AU - Trudeau, M. AU - Leighl, N. B. AU - Pullenayegum, E. AU - Khong, H. PY - 2013 DA - 2013// TI - Closing the personalized medicine information gap: HER2 test documentation practice JO - Am J Manag Care VL - 19 ID - Ferrusi2013 ER - TY - JOUR AU - Camargo, C. M. AU - Comber, H. AU - Sharp, L. PY - 2015 DA - 2015// TI - Which women with breast cancer do, and do not, undergo receptor status testing? A population-based study JO - Cancer Epidemiol VL - 39 ID - Camargo2015 ER - TY - STD TI - Greenbaum A, Wiggins C, Meisner AL, Rojo M, Kinney AY, Rajput A. KRAS biomarker testing disparities in colorectal cancer patients in New Mexico. Heliyon. 2017;(3, 11):e00448-e. ID - ref25 ER - TY - JOUR AU - Rico, A. AU - Pollack, L. A. AU - Thompson, T. D. AU - Hsieh, M. -. C. AU - Wu, X. -. C. AU - Karlitz, J. J. PY - 2016 DA - 2016// TI - KRAS testing and first-line treatment among patients diagnosed with metastatic colorectal cancer using population data from ten national program of cancer registries in the United States JO - J Cancer Res Ther (Manch). VL - 5 ID - Rico2016 ER - TY - JOUR AU - Webster, J. AU - Kauffman, T. L. AU - Feigelson, H. S. AU - Pawloski, P. A. AU - Onitilo, A. A. AU - Potosky, A. L. PY - 2013 DA - 2013// TI - KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings JO - Cancer Epidemiol Biomark Prev VL - 22 ID - Webster2013 ER - TY - JOUR AU - Presley, C. J. AU - Tang, D. AU - Soulos, P. R. AU - Chiang, A. C. AU - Longtine, J. A. AU - Adelson, K. B. PY - 2018 DA - 2018// TI - Association of broad-based genomic sequencing with survival among patients with advanced non–small cell lung cancer in the community oncology setting JO - JAMA. VL - 320 ID - Presley2018 ER - TY - JOUR AU - Du, X. L. AU - Xia, R. AU - Burau, K. AU - Liu, C. -. C. PY - 2011 DA - 2011// TI - Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005 JO - Med Oncol VL - 28 ID - Du2011 ER - TY - JOUR AU - Vaz-Luis, I. AU - Lin, N. U. AU - Keating, N. L. AU - Barry, W. T. AU - Lii, H. AU - Winer, E. P. PY - 2015 DA - 2015// TI - Racial differences in outcomes for patients with metastatic breast cancer by disease subtype JO - Breast Cancer Res Treat VL - 151 ID - Vaz-Luis2015 ER - TY - JOUR AU - Reeder-Hayes, K. AU - Hinton, S. P. AU - Meng, K. AU - Carey, L. A. AU - Dusetzina, S. B. PY - 2016 DA - 2016// TI - Disparities in use of human epidermal growth hormone receptor 2–targeted therapy for early-stage breast cancer JO - J Clin Oncol VL - 34 ID - Reeder-Hayes2016 ER - TY - JOUR AU - Vaz-Luis, I. AU - Lin, N. U. AU - Keating, N. L. AU - Barry, W. T. AU - Lii, J. AU - Burstein, H. J. PY - 2016 DA - 2016// TI - Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab JO - Breast Cancer Res Treat VL - 159 ID - Vaz-Luis2016 ER - TY - JOUR AU - Tsai, H. -. T. AU - Isaacs, C. AU - Lynce, F. C. AU - O'Neill, S. C. AU - Liu, C. AU - Schwartz, M. D. PY - 2017 DA - 2017// TI - Initiation of trastuzumab by women younger than 64 years for adjuvant treatment of stage I–III breast cancer JO - J Natl Compr Cancer Netw VL - 15 ID - Tsai2017 ER - TY - JOUR AU - Freedman, R. A. AU - Hughes, M. E. AU - Ottesen, R. A. AU - Weeks, J. C. AU - He, Y. AU - Wong, Y. -. N. PY - 2013 DA - 2013// TI - Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the national comprehensive cancer network JO - Cancer. VL - 119 ID - Freedman2013 ER - TY - JOUR AU - Haas, J. S. AU - Phillips, K. A. AU - Liang, S. -. Y. AU - Hassett, M. J. AU - Keohane, C. AU - Elkin, E. B. PY - 2011 DA - 2011// TI - Genomic testing and therapies for breast cancer in clinical practice JO - J Oncol Pract VL - 7 ID - Haas2011 ER - TY - STD TI - Goldhar HA, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, et al. The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study. J Natl Cancer Inst. 2015;108(1):djv301. ID - ref36 ER - TY - JOUR AU - Kumachev, A. AU - Trudeau, M. E. AU - Chan, K. K. W. PY - 2016 DA - 2016// TI - Associations among socioeconomic status, patterns of care, and outcomes in breast cancer patients in a universal health care system: Ontario’s experience JO - Cancer. VL - 122 ID - Kumachev2016 ER - TY - JOUR AU - Thavendiranathan, P. AU - Abdel-Qadir, H. AU - Fischer, H. D. AU - Camacho, X. AU - Amir, E. AU - Austin, P. C. PY - 2016 DA - 2016// TI - Breast cancer therapy–related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study JO - J Clin Oncol VL - 34 ID - Thavendiranathan2016 ER - TY - JOUR AU - Li, J. AU - Shao, Z. AU - Xu, B. AU - Jiang, Z. AU - Cui, S. AU - Zhang, J. PY - 2018 DA - 2018// TI - Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: the Nvwa study JO - Medicine (Baltimore) VL - 97 ID - Li2018 ER - TY - JOUR AU - Shih, Y. -. C. T. AU - Elting, L. S. AU - Halpern, M. T. PY - 2009 DA - 2009// TI - Factors associated with immunotherapy use among newly diagnosed cancer patients JO - Med Care VL - 47 ID - Shih2009 ER - TY - JOUR AU - Zhu, J. AU - Sharma, D. B. AU - Gray, S. W. AU - Chen, A. B. AU - Weeks, J. C. AU - Schrag, D. PY - 2012 DA - 2012// TI - Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non–small cell lung cancer JO - JAMA. VL - 307 ID - Zhu2012 ER - TY - JOUR AU - Langer, C. AU - Ravelo, A. AU - Hazard, S. J. AU - Guerin, A. AU - Ionescu-Ittu, R. AU - Latremouille-Viau, D. PY - 2014 DA - 2014// TI - Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab–carboplatin–paclitaxel and carboplatin–paclitaxel: a retrospective cohort study JO - Lung Cancer VL - 86 ID - Langer2014 ER - TY - JOUR AU - Ritzwoller, D. P. AU - Carroll, N. M. AU - Delate, T. AU - Hornbrook, M. C. AU - Kushi, L. AU - Bowles, E. J. A. PY - 2014 DA - 2014// TI - Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experience JO - J Thorac Oncol VL - 9 ID - Ritzwoller2014 ER - TY - JOUR AU - Menter, A. R. AU - Carroll, N. M. AU - Sakoda, L. C. AU - Delate, T. AU - Hornbrook, M. C. AU - Jain, R. K. PY - 2017 DA - 2017// TI - Effect of angiotensin system inhibitors on survival in patients receiving chemotherapy for advanced non–small-cell lung cancer JO - Clin Lung Cancer VL - 18 ID - Menter2017 ER - TY - STD TI - Maguire FB, Morris CR, Parikh-Patel A, Cress RD, Keegan THM, Li C-S, et al. First-line systemic treatments for stage IV non-small cell lung cancer in California: patterns of care and outcomes in a real-world setting. JNCI Cancer Spectrum. 2019b;3(3):pkz020. ID - ref45 ER - TY - JOUR AU - Verma, V. AU - Haque, W. AU - Cushman, T. R. AU - Lin, C. AU - II CBS, Chang JY, et al. PY - 2019 DA - 2019// TI - Racial and insurance-related disparities in delivery of immunotherapy-type compounds in the United States JO - J Immunother VL - 42 ID - Verma2019 ER - TY - JOUR AU - Lairson, D. R. AU - Parikh, R. C. AU - Cormier, J. N. AU - Chan, W. AU - Du, X. L. PY - 2015 DA - 2015// TI - Cost-utility analysis of treatments for advanced non-small cell lung cancer JO - Am J Pharm Benefits VL - 7 ID - Lairson2015 ER - TY - JOUR AU - Sahara, K. AU - Farooq, S. A. AU - Tsilimigras, D. I. AU - Merath, K. AU - Paredes, A. Z. AU - Wu, L. PY - 2019 DA - 2019// TI - Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status JO - Hepatobiliary Surg Nutr VL - 9 ID - Sahara2019 ER - TY - JOUR AU - Sanoff, H. K. AU - Chang, Y. AU - Lund, J. L. AU - O'Neil, B. H. AU - Dusetzina, S. B. PY - 2016 DA - 2016// TI - Sorafenib effectiveness in advanced hepatocellular carcinoma JO - Oncologist. VL - 21 ID - Sanoff2016 ER - TY - JOUR AU - Parsons, H. M. AU - Chu, Q. AU - Karlitz, J. J. AU - Stevens, J. L. AU - Harlan, L. C. PY - 2017 DA - 2017// TI - Adoption of sorafenib for the treatment of advanced-stage hepatocellular carcinoma in oncology practices in the United States JO - Liver Cancer VL - 6 ID - Parsons2017 ER - TY - JOUR AU - Sarpel, U. AU - Heskel, M. AU - Spivack, J. H. AU - Feferman, Y. AU - Ang, C. AU - Gany, F. PY - 2018 DA - 2018// TI - Disparities in access to sorafenib in communities with low socioeconomic status JO - J Health Care Poor Underserved VL - 29 ID - Sarpel2018 ER - TY - JOUR AU - Al-Qurayshi, Z. AU - Crowther, J. E. AU - Hamner, J. B. AU - Ducoin, C. AU - Killackey, M. T. AU - Kandil, E. PY - 2018 DA - 2018// TI - Disparities of immunotherapy utilization in patients with stage III cutaneous melanoma: a national perspective JO - Anticancer Res VL - 38 ID - Al-Qurayshi2018 ER - TY - JOUR AU - Haque, W. AU - Verma, V. AU - Butler, E. B. AU - Teh, B. S. PY - 2019 DA - 2019// TI - Racial and socioeconomic disparities in the delivery of immunotherapy for metastatic melanoma in the United States JO - J Immunother VL - 42 ID - Haque2019 ER - TY - JOUR AU - Fu, A. Z. AU - Tsai, H. -. T. AU - Marshall, J. L. AU - Freedman, A. N. AU - Potosky, A. L. PY - 2014 DA - 2014// TI - Utilization of bevacizumab in US elderly patients with colorectal cancer receiving chemotherapy JO - J Oncol Pharm Pract VL - 20 ID - Fu2014 ER - TY - JOUR AU - Meyerhardt, J. A. AU - Li, L. AU - Sanoff, H. K. AU - Carpenter, W. AU - Schrag, D. PY - 2012 DA - 2012// TI - Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer JO - J Clin Oncol VL - 30 ID - Meyerhardt2012 ER - TY - JOUR AU - Cen, P. AU - Liu, C. AU - Du, X. L. PY - 2012 DA - 2012// TI - Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer JO - Ann Oncol VL - 23 ID - Cen2012 ER - TY - JOUR AU - Parikh, R. C. AU - Du, X. L. AU - Morgan, R. O. AU - Lairson, D. R. PY - 2016 DA - 2016// TI - Patterns of treatment sequences in chemotherapy and targeted biologics for metastatic colorectal cancer: findings from a large community-based cohort of elderly patients JO - Drugs Real World Outcomes VL - 3 ID - Parikh2016 ER - TY - JOUR AU - Neugut, A. I. AU - Becker, D. J. AU - Insel, B. J. AU - Hershman, D. L. PY - 2012 DA - 2012// TI - Uptake of oxaliplatin and bevacizumab for treatment of node-positive and metastatic colon cancer JO - J Oncol Pract VL - 8 ID - Neugut2012 ER - TY - JOUR AU - Raab, G. T. AU - Lin, A. AU - Hillyer, G. C. AU - Keller, D. AU - O’Neil, D. S. AU - Accordino, M. K. PY - 2019 DA - 2019// TI - Use of bevacizumab for elderly patients with stage IV colon cancer: analysis of SEER-Medicare data JO - Clin Colorectal Cancer VL - 18 ID - Raab2019 ER - TY - JOUR AU - Taylor, J. P. AU - Stem, M. AU - Yu, D. AU - Chen, S. Y. AU - Fang, S. H. AU - Gearhart, S. L. PY - 2019 DA - 2019// TI - Treatment strategies and survival trends for anorectal melanoma: is it time for a change? JO - World J Surgery VL - 43 ID - Taylor2019 ER - TY - JOUR AU - Saigal, C. S. AU - Deibert, C. M. AU - Lai, J. AU - Schonlau, M. PY - 2010 DA - 2010// TI - Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma JO - Urol Oncol VL - 28 ID - Saigal2010 ER - TY - JOUR AU - Amini, A. AU - Eguchi, M. AU - Jones, B. L. AU - Stokes, W. A. AU - Gupta, A. AU - McDermott, J. D. PY - 2018 DA - 2018// TI - Comparing outcomes of concurrent chemotherapy regimens in patients 65 years old or older with locally advanced oropharyngeal carcinoma JO - Cancer. VL - 124 ID - Amini2018 ER - TY - JOUR AU - Xiang, M. AU - Holsinger, F. C. AU - Colevas, A. D. AU - Chen, M. M. AU - Le, Q. -. T. AU - Beadle, B. M. PY - 2018 DA - 2018// TI - Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: a Surveillance, Epidemiology, and End Results-Medicare analysis JO - Cancer. VL - 124 ID - Xiang2018 ER - TY - JOUR AU - Hershman, D. L. AU - Wright, J. D. AU - Lim, E. AU - Buono, D. L. AU - Tsai, W. Y. AU - Neugut, A. I. PY - 2013 DA - 2013// TI - Contraindicated use of bevacizumab and toxicity in elderly patients with cancer JO - J Clin Oncol VL - 31 ID - Hershman2013 ER - TY - JOUR AU - Mohile, S. G. AU - Hardt, M. AU - Tew, W. AU - Owusu, C. AU - Klepin, H. AU - Gross, C. PY - 2013 DA - 2013// TI - Toxicity of bevacizumab in combination with chemotherapy in older patients JO - Oncologist. VL - 18 ID - Mohile2013 ER - TY - JOUR AU - Enewold, L. AU - Sharon, E. AU - Harlan, L. C. PY - 2017 DA - 2017// TI - Metastatic melanoma: treatment and survival in the US after the introduction of ipilimumab and vemurafenib JO - Oncology Res Treat VL - 40 ID - Enewold2017 ER - TY - JOUR AU - Enewold, L. AU - Thomas, A. PY - 2016 DA - 2016// TI - Real-world patterns of EGFR testing and treatment with erlotinib for non-small cell lung cancer in the United States JO - PLoS One VL - 11 ID - Enewold2016 ER - TY - JOUR AU - Palazzo, L. L. AU - Sheehan, D. F. AU - Tramontano, A. C. AU - Kong, C. Y. PY - 2019 DA - 2019// TI - Disparities and trends in genetic testing and erlotinib treatment among metastatic non–small cell lung cancer patients JO - Cancer Epidemiology Biomarkers Prev. VL - 28 ID - Palazzo2019 ER - TY - JOUR AU - Freedman, R. A. AU - Vaz-Luis, I. AU - Barry, W. T. AU - Lii, H. AU - Lin, N. U. AU - Winer, E. P. PY - 2014 DA - 2014// TI - Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy JO - Breast Cancer Res Treat VL - 145 ID - Freedman2014 ER - TY - JOUR AU - Vaz-Luis, I. AU - Keating, N. L. AU - Lin, N. U. AU - Lii, H. AU - Winer, E. P. AU - Freedman, R. A. PY - 2014 DA - 2014// TI - Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study JO - J Clin Oncol VL - 32 ID - Vaz-Luis2014 ER - TY - JOUR AU - Reeder-Hayes, K. E. AU - Meyer, A. M. AU - Hinton, S. P. AU - Meng, K. AU - Carey, L. A. AU - Dusetzina, S. B. PY - 2017 DA - 2017// TI - Comparative toxicity and effectiveness of trastuzumab-based chemotherapy regimens in older women with early-stage breast cancer JO - J Clinic Oncol VL - 35 ID - Reeder-Hayes2017 ER - TY - JOUR AU - Chavez-MacGregor, M. AU - Niu, J. AU - Zhang, N. AU - Elting, L. S. AU - Smith, B. D. AU - Banchs, J. PY - 2015 DA - 2015// TI - Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older patients with breast cancer JO - J Clin Oncol VL - 33 ID - Chavez-MacGregor2015 ER - TY - JOUR AU - Lu, C. Y. AU - Srasuebkul, P. AU - Drew, A. K. AU - Chen, K. AU - Ward, R. L. AU - Pearson, S. -. A. PY - 2013 DA - 2013// TI - Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function? JO - Breast. VL - 22 ID - Lu2013 ER - TY - JOUR AU - Krimphove, M. J. AU - Tully, K. H. AU - Friedlander, D. F. AU - Marchese, M. AU - Ravi, P. AU - Lipsitz, S. R. PY - 2019 DA - 2019// TI - Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma JO - J Immunother Cancer VL - 7 ID - Krimphove2019 ER - TY - JOUR AU - Zheng, Z. AU - Hanna, N. AU - Onukwugha, E. AU - Reese, E. S. AU - Seal, B. AU - Mullins, C. D. PY - 2014 DA - 2014// TI - Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3,211 metastatic colon cancer patients JO - Cancer Med VL - 3 ID - Zheng2014 ER - TY - JOUR AU - Kwan, S. W. AU - Harris, W. P. AU - Gold, L. S. AU - Hebert, P. L. PY - 2018 DA - 2018// TI - Comparative effectiveness of transarterial embolization and sorafenib for hepatocellular carcinoma: a population-based study JO - Am J Roentgenol VL - 210 ID - Kwan2018 ER - TY - JOUR AU - Li, P. AU - Jahnke, J. AU - Pettit, A. R. AU - Wong, Y. -. N. AU - Doshi, J. A. PY - 2019 DA - 2019// TI - Comparative survival associated with use of targeted vs nontargeted therapy in medicare patients with metastatic renal cell carcinoma JO - JAMA Netw Open VL - 2 ID - Li2019 ER - TY - JOUR AU - Zandberg, D. P. AU - Cullen, K. AU - Bentzen, S. M. AU - Goloubeva, O. G. PY - 2018 DA - 2018// TI - Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: analysis of the SEER-medicare linked database JO - Oral Oncol VL - 86 ID - Zandberg2018 ER - TY - JOUR AU - Thavendiranathan, P. AU - Abdel-Qadir, H. AU - Fischer, H. D. AU - Liu, Y. AU - Camacho, X. AU - Amir, E. PY - 2018 DA - 2018// TI - Risk-imaging mismatch in cardiac imaging practices for women receiving systemic therapy for early-stage breast cancer: a population-based cohort study JO - J Clin Oncol VL - 36 ID - Thavendiranathan2018 ER - TY - JOUR AU - Delate, T. AU - Won, K. AU - Nm, C. AU - Kushi, L. AU - Hornbrook, M. AU - Eja, B. PY - 2014 DA - 2014// TI - Factors associated with first-line bevacizumab use in advanced non-squamous non-small cell lung cancer JO - J Cancer Res Ther (Manch) VL - 2 ID - Delate2014 ER - TY - JOUR AU - Carroll, N. M. AU - Delate, T. AU - Menter, A. AU - Hornbrook, M. C. AU - Kushi, L. AU - Bowles, E. J. A. PY - 2015 DA - 2015// TI - Use of bevacizumab in community settings: toxicity profile and risk of hospitalization in patients with advanced non–small-cell lung cancer JO - J Oncol Pract. VL - 11 ID - Carroll2015 ER - TY - JOUR AU - Maguire, F. B. AU - Morris, C. R. AU - Parikh-Patel, A. AU - Cress, R. D. AU - Keegan, T. H. M. AU - Li, C. -. S. PY - 2019 DA - 2019// TI - Disparities in systemic treatment use in advanced-stage non–small cell lung cancer by source of health insurance JO - Cancer Epidemiol Biomarkers Prev VL - 28 ID - Maguire2019 ER - TY - JOUR AU - Smith, D. AU - Thomson, K. AU - Bambra, C. AU - Todd, A. PY - 2019 DA - 2019// TI - The breast cancer paradox: a systematic review of the association between area-level deprivation and breast cancer screening uptake in Europe JO - Cancer Epidemiol VL - 60 ID - Smith2019 ER - TY - JOUR AU - Lyratzopoulos, G. AU - Abel, G. A. AU - Brown, C. H. AU - Rous, B. A. AU - Vernon, S. A. AU - Roland, M. PY - 2013 DA - 2013// TI - Socio-demographic inequalities in stage of cancer diagnosis: evidence from patients with female breast, lung, colon, rectal, prostate, renal, bladder, melanoma, ovarian and endometrial cancer JO - Ann Oncol VL - 24 ID - Lyratzopoulos2013 ER - TY - STD TI - Hayes L AJ, McCallum I, Forrest L, Hidajat M, White M, Sharp L. Age-related and socio-economic inequalities in timeliness of referral and start of treatment in colorectal cancer. A population-based analysis J Epi Comm Health 2020; in press. ID - ref85 ER - TY - JOUR AU - Woods, L. M. AU - Rachet, B. AU - Coleman, M. P. PY - 2006 DA - 2006// TI - Origins of socio-economic inequalities in cancer survival: a review JO - Ann Oncol VL - 17 ID - Woods2006 ER - TY - STD TI - Network NCI. Evidence to March 2010 on cancer inequalities in England. 2010. www.ncin.org.uk/inequalities. Accessed 17 Mar 2020. UR - http://www.ncin.org.uk/inequalities ID - ref87 ER - TY - JOUR AU - Sarfati, D. AU - Koczwara, B. AU - Jackson, C. PY - 2016 DA - 2016// TI - The impact of comorbidity on cancer and its treatment JO - CA Cancer J Clin VL - 66 ID - Sarfati2016 ER - TY - STD TI - Dahlgren G, Whitehead M. Tackling inequalities in health: what can we learn from what has been tried? Working paper prepared for the King’s Fund international seminar on tackling inequalities in health, September 1993, Ditchley Park, Oxfordshire. London, King’s Fund. In: Dahlgren G, Whitehead M, editors. European strategies for tackling social inequities in health: Levelling up part 2 Copenhagen: WHO Regional Office for Europe 2007. p. 20–32. ID - ref89 ER - TY - JOUR AU - Martin, A. P. AU - Downing, J. AU - Cochrane, M. AU - Collins, B. AU - Francis, B. AU - Haycox, A. PY - 2018 DA - 2018// TI - Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies JO - Crit Rev Oncol/Hematol VL - 130 ID - Martin2018 ER - TY - JOUR AU - Osbourne, C. K. PY - 1998 DA - 1998// TI - Steroid hormone receptors in breast cancer management JO - Breast Cancer Res Treat VL - 51 ID - Osbourne1998 ER - TY - JOUR AU - Victora, C. G. AU - Vaughan, J. P. AU - Barros, F. C. AU - Silva, A. C. AU - Tomasi, E. PY - 2000 DA - 2000// TI - Explaining trends in inequities: evidence from Brazilian child health studies JO - Lancet. VL - 356 ID - Victora2000 ER - TY - BOOK AU - Rodgers, E. PY - 2003 DA - 2003// TI - Diffusion of innovations PB - Schuster International CY - New York ID - Rodgers2003 ER - TY - CHAP AU - White, M. AU - Adams, J. AU - Heywood, P. ED - Babones, S. J. PY - 2012 DA - 2012// TI - How and why do interventions that increase health overall widen inequalities within populations? BT - Social inequality and public health PB - Policy Press CY - Bristol ID - White2012 ER - TY - JOUR AU - Tseng, C. -. H. AU - Chiang, C. -. J. AU - Tseng, J. -. S. AU - Yang, T. -. Y. AU - Hsu, K. -. H. AU - Chen, K. -. C. PY - 2017 DA - 2017// TI - EGFR mutation, smoking, and gender in advanced lung adenocarcinoma JO - Oncotarget. VL - 8 ID - Tseng2017 ER - TY - STD TI - Lung Cancer Coalition. Molecules matter turning the science of molecular diagnostics in lung cancer into a practical service for all patients. 2019. https://www.uklcc.org.uk/wp-content/uploads/2019/01/Molecules-Matter.pdf. Accessed 15 Mar 2020. UR - https://www.uklcc.org.uk/wp-content/uploads/2019/01/Molecules-Matter.pdf ID - ref96 ER - TY - JOUR AU - Lee, D. H. AU - Tsao, M. -. S. AU - Kambartel, K. -. O. AU - Isobe, H. AU - Huang, M. -. S. AU - Barrios, C. H. PY - 2018 DA - 2018// TI - Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study JO - PloS One VL - 13 ID - Lee2018 ER - TY - JOUR AU - Illei, P. B. AU - Wong, W. AU - Wu, N. AU - Chu, L. AU - Gupta, R. AU - Schulze, K. PY - 2018 DA - 2018// TI - ALK testing trends and patterns among community practices in the United States JO - JCO Precis Oncol VL - 2 ID - Illei2018 ER - TY - STD TI - Cancer Research UK. Cancer Research UK policy statement: patient access to molecular diagnostics and targeted medicines in England. 2018. https://www.cancerresearchuk.org/sites/default/files/access_to_molecular_diagnostic_tests_and_targeted_medicines_in_england_0.pdf. Accessed 15 Mar 2020. UR - https://www.cancerresearchuk.org/sites/default/files/access_to_molecular_diagnostic_tests_and_targeted_medicines_in_england_0.pdf ID - ref99 ER - TY - STD TI - Deeks JJ, Higgins JPT, Altman DG. Chapter 10: analysing data and undertaking meta-analyses, Section 4.6.4 In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 510 [updated March 2011]. Chichester: Wiley; 2011. ID - ref100 ER - TY - JOUR AU - Galobardes, B. AU - Shaw, M. AU - Lawlor, D. A. AU - Lynch, J. W. AU - Davey, S. G. PY - 2006 DA - 2006// TI - Indicators of socioeconomic position (part 1) JO - Journal Epidemiol Community Health VL - 60 ID - Galobardes2006 ER - TY - JOUR AU - Bach, P. B. AU - Guadagnoli, E. AU - Schrag, D. AU - Schussler, N. AU - Warren, J. L. PY - 2002 DA - 2002// TI - Patient demographic and socioeconomic characteristics in the SEER-Medicare database: applications and limitations JO - Med Care VL - 40 ID - Bach2002 ER - TY - JOUR AU - Griggs, J. J. PY - 2012 DA - 2012// TI - Role of nonclinical factors in the receipt of high-quality systemic adjuvant breast cancer treatment JO - J Clinical Oncol VL - 30 ID - Griggs2012 ER - TY - JOUR AU - Goss, E. AU - Lopez, A. M. AU - Brown, C. L. AU - Wollins, D. S. AU - Brawley, O. W. AU - Raghavan, D. PY - 2009 DA - 2009// TI - American Society of Clinical Oncology policy statement: disparities in cancer care JO - J Clin Oncol VL - 27 ID - Goss2009 ER -